Mildronate (Meldonium Dihydrate)

Meldonium inhibits γ‑butyrobetaine hydroxylase, which lowers intracellular carnitine levels. This shift reduces fatty‑acid oxidation and promotes glucose oxidation in heart muscle, providing a more efficient energy source during low‑oxygen conditions and helping protect cardiac cells from ischemic injury.

The dosage of Mildronate is individualized and determined by the prescribing physician based on the patient’s clinical condition, severity of disease, and response to therapy. No fixed regimen is provided here; the prescriber sets the appropriate dose.

Safety data for Meldonium in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Mildronate product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Mildronate differs from traditional anti‑anginal agents such as nitrates or beta‑blockers by targeting myocardial metabolism rather than vascular tone. While nitrates dilate coronary vessels and beta‑blockers reduce heart rate, Meldonium improves the heart’s energy efficiency, offering a complementary mechanism for patients who need metabolic support.

Mildronate should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain its stability and potency.

Mildronate is supplied as an injectable solution for intravenous administration. The preparation is given by a qualified healthcare professional under aseptic conditions, typically in a clinical or hospital setting.

Serious adverse reactions include arrhythmia, severe hypotension, and anaphylactic-type allergic responses. Patients should be monitored for any signs of irregular heart rhythm, sudden drops in blood pressure, or severe allergic symptoms, and treatment should be discontinued immediately if these occur.

Mildronate is contraindicated in individuals with known hypersensitivity to Meldonium or any excipients in the formulation. Caution is also advised for patients with severe renal impairment, uncontrolled hypotension, or those taking medications that may cause dangerous additive effects, as outlined in the interaction section.